Helixgate https://validator.w3.org/feed/docs/rss2.html Lab automation strong despite global challenges Home Digital PCR Playbook: Applications and Challenges Across Research and Clinical Labs Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles Science is becoming less disruptive. Is an aging workforce to blame? FDA pilots AI-informed one-day facility inspections Amazon adds Ozempic pill to same-day prescription drug kiosks Official leading CDC’s cruise ship program retires EnGene’s shares crash on updated pivotal bladder cancer data Angelini to buy Catalyst in $4B play for rare neuro drugs FDA reverses course on Atara, Pierre Fabre’s twice-rejected cell therapy after Prasad’s exit STAT+: More political interference at the FDA? Angelini inks $4.1B Catalyst buy to enter US rare disease market Gilead wipes out most of Arcellx workforce Amgen adds $300M to Puerto Rico budget; Novartis to exit oral drug factory in Germany STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more Entrada crashes as Duchenne therapy comes in ‘below expectations’ in early study Next Gen Leadership Awards Presented at the AGBT Agricultural Meeting Atara, Pierre Fabre’s cell therapy to get another shot at FDA approval Sanofi requests removal of Tzield from CNPV program after Høeg gets involved Pennsylvania sues AI chatbot company for posing as a licensed doctor Sarepta says to ‘exercise prudence’ in setting expectations for Elevidys’ recovery STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection GSK goes beyond weight-loss with $1B buyout of Chinese siRNA specialist Hospital shootings steadily increased since 2000 Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst Pharma STAT+: Color me skeptical: Drinking gold is not an ALS cure STAT+: Administration report on most favored nation drug pricing raises new details — and questions STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B STAT+: Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with review Fibrosis, IPF and the search for better therapies STAT+: Oregon hospitals won’t outsource to national physician chain after all Microproteins and Peptideins Expand Boundaries of the Human Proteome Trump administration’s drug strategy is at odds with recent actions on funding, policy Amgen, AbbVie say IRA negotiations impacted Q1 sales Lilly plans new $4.5B manufacturing investment in Indiana Increased capital boosts biotech R&D job postings, employment Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline Winning the room: how to ace panel interviews From Discovery to GMP: Building Scalable Cell Therapy Manufacturing Heavy-Chain BsAbs More Manufacturable than Light-Chains Amgen, Sanofi commit nearly $600M to North American expansions Novo hikes guidance on Wegovy pill’s fast sales start CoCoGraph AI Model Generates Molecules that Comply with Rules of Chemistry Madrigal’s Rezdiffra beats estimates; Gilead cuts jobs; Banyan debuts Ipsen scuttles liver disease candidates from $952M Albireo acquisition Unforced errors flummox HHS’ radical transparency bid—again Avalo shares spike on skin drug data; BioNTech to cut staff 3 top FDA, CDC roles filled by 15 different people in less than 18 months Bayer to Acquire Perfuse for up to $2.45B, Seeing Ophthalmology Opportunity